FOLH1 and pachyonychia congenita: Supporting the notion that safety and efficacy profiles of both radioligands are less likely to be interchangeable, the current literature comprises only a limited number of approximately 100 subjects treated with [177Lu]Lu-PSMA I&T, which is in contrast to more than 900 reported patients with PC treated with [177Lu]Lu-PSMA-617 [15].